BPC-157

What Is BPC-157?

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide composed of 15 amino acids, derived from a protective protein originally isolated from human gastric juice. Developed through gastric cytoprotective research, it is primarily evaluated in animal models and limited early human studies for tissue repair, gut healing, and systemic anti-inflammatory activity. BPC-157 is a research compound and is not FDA-approved for therapeutic use.

The name “body protection compound 157” reflects its early association with gastric cytoprotective research and gastrointestinal tissue protection. Preclinical investigations have explored its effects across models of tendon injury, muscle recovery, intestinal inflammation, and connective tissue repair, making BPC-157 peptide protocols a frequent topic in regenerative medicine and sports injury research.

The available evidence base consists almost entirely of animal studies and in vitro investigations. Published human randomized controlled trial evidence is extremely sparse, and clinical trials in this area appear to have been discontinued or halted without published conclusions. Human safety and efficacy have not been established.

Those researching where to buy BPC-157 peptide for investigational use can contact Medica Depot’s support representatives for documentation and sourcing guidance.

Mechanism of Action

BPC-157 appears to work through angiogenic, anti-inflammatory, and cytoprotective pathways. One of its most studied mechanisms involves upregulation of vascular endothelial growth factor (VEGF), which may support angiogenesis and blood vessel formation at injury sites. Improved vascular supply can enhance tissue perfusion and nutrient delivery during healing.

Research also suggests that BPC-157 modulates nitric oxide (NO) pathways involved in circulation, vascular tone, and inflammatory regulation. Through this activity, the peptide may contribute to improved microvascular stability and tissue recovery in preclinical injury models.

In studies of tendon and connective tissue, researchers observed increased growth hormone receptor expression in fibroblasts and tendon cells. Unlike GH secretagogues that stimulate pituitary HGH release, BPC-157 acts locally at the tissue level without significantly elevating IGF-1 concentrations.

Preclinical rodent studies have also reported reductions in TNF-alpha and other inflammatory cytokines, alongside preservation of gut mucosal integrity, in ulceration and inflammatory bowel disease models. Neuroprotective effects involving modulation of dopaminergic and serotonergic pathways have also been described, though controlled human evidence remains limited and primarily preclinical.

Does BPC-157 Affect HGH Levels?

BPC-157 is not a growth hormone secretagogue and does not directly stimulate pituitary HGH release or significantly increase IGF-1 levels. Published research suggests the peptide primarily acts at the tissue level, particularly within tendons, fibroblasts, and other connective tissue structures involved in repair processes.

Preclinical studies indicate that BPC-157 may increase local growth hormone receptor expression in peripheral tissues. This receptor-level observation has been proposed in preclinical models as a mechanism that might theoretically influence local tissue sensitivity to growth hormone.

No human data currently confirm this functional effect, and it should not be interpreted as an established clinical outcome.

This distinction is relevant when comparing BPC-157 with GH secretagogues such as Sermorelin or CJC-1295. Those compounds stimulate upstream hormonal pathways that increase HGH pulsatility and IGF-1 production, whereas BPC-157 focuses on angiogenesis, tissue repair, and anti-inflammatory mechanisms. This distinction is relevant in research protocols where GH-axis stimulation may be undesirable, though BPC-157 also lacks the broader anabolic and body-composition effects associated with elevated HGH or IGF-1 activity.

BPC-157 Benefits

Discussion of BPC-157 benefits should remain evidence-based, as the majority of supporting data currently comes from animal models and preclinical research.

Musculoskeletal Repair

The most extensively studied application involves tendon, ligament, and muscle healing. Animal model research has demonstrated accelerated tendon repair, improved collagen organization, and enhanced tendon-to-bone integration following BPC 157 injection protocols. These findings have contributed to growing interest within sports medicine and regenerative research settings.

Gut Healing

BPC-157 was originally developed through research on human gastric tissue, making gastrointestinal applications a central area of investigation. Rodent studies have explored cytoprotective effects in inflammatory bowel disease and ulcerative colitis models, as well as in models of gut permeability disruption.

Published human clinical trial data for BPC-157 remain extremely sparse. Early-phase human gastrointestinal observations have been reported, though planned trials in this area appear to have been discontinued without published conclusions, and no randomized controlled trials currently confirm efficacy in humans

Systemic Anti-Inflammatory Activity

Preclinical investigations have reported reductions in TNF-alpha and other inflammatory cytokines across multiple tissue systems. This broad anti-inflammatory profile has expanded interest in BPC-157 peptide protocols involving chronic inflammation and tissue stress responses.

Neuroprotection

Rodent traumatic brain injury and neurotoxicity studies have suggested possible dopaminergic stabilization and serotonergic pathway modulation. These findings remain early-stage and should be interpreted as preclinical observations rather than established outcomes.

BPC-157 Dosage & Administration

No FDA-validated dosing framework currently exists for BPC-157. All dosing references are practitioner-reported, research-derived, or based on preclinical literature rather than on controlled therapeutic guidelines.

In subcutaneous administration protocols, BPC 157 injection doses commonly referenced in the research literature range from 200 to 500 mcg daily. Some practitioners reference localized injections near injured tissue sites, particularly in tendon or ligament-focused protocols. A typical BPC 157 dosing chart used in research contexts may consider body weight, injury severity, and treatment duration, though these models remain extrapolated rather than clinically standardized.

BPC-157 dosage per body weight calculations should be interpreted with caution because no consensus on controlled human dosing currently exists.

Oral administration has primarily been evaluated in gut-specific animal models. Rodent studies explored oral dosing ranges of 1-10 mcg/kg, though direct translation to human oral BPC-157 capsules remains speculative and insufficiently validated.

Additional handling considerations commonly referenced in practitioner protocols include:

• Daily administration or 5-days-on/2-days-off cycling
• Common cycle durations of 4 to 12 weeks
• Reconstitution using bacteriostatic water
• Refrigerated storage at 2 to 8°C after mixing
• Protection from direct light exposure

Researchers and practitioners buying online should prioritize suppliers with documented batch traceability, third-party purity verification, and consistent storage handling standards. Those looking to buy BPC-157 wholesale for institutional or multi-practitioner research settings can contact Medica Depot’s support representatives for documentation and sourcing guidance.

Legal Status of BPC-157

Before evaluating or procuring any research peptide compound, practitioners should confirm the regulations applicable to their jurisdiction. Research institutions assessing supply logistics for laboratory or multi-practitioner settings may also benefit from reviewing wholesale pricing structures when comparing procurement options.

• United States: BPC-157 is not FDA-approved for therapeutic use. In September 2023, the FDA classified BPC-157 as a Category 2 substance under its Interim Policy on Compounding Using Bulk Drug Substances, prohibiting its use by both 503A and 503B compounding pharmacies due to insufficient safety data and a lack of human efficacy evidence. FDA’s regulatory position regarding compounded peptides has remained under active review into 2026, with advisory committee meetings scheduled to further evaluate the compounding status of certain peptides. Practitioners should verify BPC-157’s current status directly against the most recent FDA guidance before evaluating any protocol.
• Australia: BPC-157 is not approved by the Therapeutic Goods Administration (TGA) for therapeutic use and is not listed on the Australian Register of Therapeutic Goods (ARTG). Practitioners should confirm the current TGA status before evaluation or procurement.
• WADA: BPC-157 has been listed on the World Anti-Doping Agency Prohibited List under S0 Non-Approved Substances since January 2022 and is prohibited at all times, including out of competition. It is not eligible for a Therapeutic Use Exemption (TUE). Documented anti-doping violations involving BPC-157 have been recorded, including formal sanctions. Practitioners working with competitive athletes should communicate this prohibition clearly and advise athletes to consult the current WADA Prohibited List directly.
• International: Regulations vary significantly across jurisdictions. Practitioners evaluating BPC-157 should carefully review local legislation, importation rules, and professional compliance requirements before proceeding.

BPC-157 Side Effects & Safety Profile

Available research suggests BPC-157 is generally well tolerated in preclinical studies, though long-term human safety data remain limited. Most evidence comes from animal models and early-stage research protocols rather than large controlled clinical trials. No major systemic toxicities have been identified in the available literature, but these evidence gaps should be clearly communicated during institutional review processes.

General Tolerability

Animal studies evaluating BPC-157 generally report favorable tolerability profiles. Controlled long-term human safety studies remain unavailable, limiting conclusions regarding chronic exposure and extended-duration protocols.

Injection Site Reactions

The most commonly reported effects following subcutaneous administration involve mild local reactions, including temporary redness, swelling, or irritation, consistent with other injectable research peptides.

Systemic Safety Findings

Preclinical literature has not documented serious adverse events or major systemic toxicities directly linked to BPC-157. However, the absence of controlled long-term human data means safety conclusions remain uncertain.

• Theoretical Oncological Concern: Because BPC-157 promotes angiogenesis via VEGF upregulation, there is a theoretical concern that this mechanism could support tumor vascularization in susceptible individuals. No direct evidence of tumor promotion has been documented in the available preclinical literature, but this remains an unresolved safety question that researchers should account for when designing protocols.

Oral Administration Considerations

Some practitioner-reported oral protocols describe nausea or mild gastrointestinal discomfort. Researchers have also theorized that modulation of the nitric oxide pathway could contribute to transient hypotension in susceptible individuals, though controlled human evidence for this effect remains limited.

BPC-157 vs Thymosin Beta-4 vs GHK-Cu vs KPV

Compared with Thymosin Beta-4, GHK-Cu, and KPV, BPC-157 occupies a distinct position due to its broad research profile spanning angiogenesis, gastrointestinal health, and tendon healing. While some overlap exists among regenerative peptide protocols, BPC-157’s VEGF-mediated tissue repair mechanisms set it apart from broader regenerative- or cosmetic-focused compounds.

Where Can Practitioners Buy BPC-157 Online?

BPC-157 is available for procurement exclusively by qualified professionals — including sports medicine physicians, regenerative medicine specialists, gastroenterologists, and institutional research buyers evaluating this compound for laboratory or investigational use. Given BPC-157’s restricted compounding status in the United States following its FDA Category 2 classification in September 2023, sourcing should be limited to suppliers that provide verifiable purity documentation, certificate of analysis, LOT number traceability, and cold-chain compliance records. Medica Depot provides documentation guidance and procurement support for qualified professionals evaluating research-grade tissue repair compounds.

Contact Medica Depot’s support representatives for guidance with sourcing documentation, product references, and purchase-related inquiries.

FAQs

1. What is BPC-157, and what is it used for?

BPC-157 is a synthetic 15-amino-acid peptide derived from a protective protein found in human gastric juice. Research primarily focuses on tissue repair, gut healing, angiogenesis, and anti-inflammatory applications across musculoskeletal and gastrointestinal models. Most evidence currently comes from preclinical animal studies and limited early human gastrointestinal data. It is a research compound and is not approved for therapeutic use.

2. Does BPC-157 increase HGH or IGF-1?

BPC-157 does not directly stimulate growth hormone release or increase IGF-1 levels. Preclinical studies suggest it may enhance local growth hormone receptor expression in connective tissues, improving sensitivity to endogenous GH without affecting the hypothalamic-pituitary axis. Unlike GH secretagogues, it does not alter systemic endocrine signaling.

3. What is the difference between BPC-157 and TB-500?

TB-500 (Thymosin Beta-4) promotes tissue regeneration primarily through actin polymerization and cell migration pathways. BPC-157 targets angiogenesis, nitric oxide modulation, and gastrointestinal protection via VEGF-related mechanisms. Both peptides are commonly discussed in regenerative research protocols and are sometimes evaluated in combination for broader tissue repair coverage.

4. Is BPC-157 legal?

BPC-157 is not FDA-approved and was removed from the FDA 503A compounding list in the United States. It has been listed on the WADA Prohibited List under S0 (Non-Approved Substances) since January 2022 and is prohibited at all times, including out of competition. It is not eligible for a Therapeutic Use Exemption. Regulatory status varies by country and can change over time; practitioners should verify current local regulations before evaluating any protocol involving BPC-157.

5. How is BPC-157 administered?

BPC-157 is most commonly referenced in practitioner protocols as a subcutaneous injection at doses of 200 to 500 mcg daily, sometimes administered near the injury site for localized effects. Oral administration has been studied primarily for gut-specific applications in animal models, though dosing translation to humans remains speculative. No FDA-approved dosing or administration guidelines currently exist.

Citations

1. Seiwerth S, Milavic M, Vukojevic J, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021;12:627533. Published 2021 Jun 29. doi:10.3389/fphar.2021.627533
2. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010
3. Keremi B, Lohinai Z, Komora P, et al. Antiinflammatory effect of BPC 157 on experimental periodontitis in rats. J Physiol Pharmacol. 2009;60 Suppl 7:115-122.
4. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Food and Drug Administration, US Dept of Health and Human Services. Updated May 14, 2026. https://www.fda.gov/media/94155/download

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.